Fig. 5: Combinatorial screening of antiplatelet drugs on the C-chip.

a Heatmap of drug combination tests for volunteer 1. b Anti-aggregation efficiency of single-drug combinations for platelets in the combinatorial screening tests for Volunteer 1. For Aspirin (Asp), the concentrations were 2 μM, 4 μM (2 μM + 2 μM), 20 μM, 22 μM (2 μM + 20 μM), and 40 μM (20 μM + 20 μM). For Tirofiban (Tif), the concentrations were 0.2 μM, 0.4 μM (0.2 μM + 0.2 μM), 2 μM, 2.2 μM (0.2 μM + 2 μM), and 4 μM (2 μM + 2 μM). For Ticagrelor, the concentrations were 1 μM, 2 μM (1 μM + 1 μM), 10 μM, 11 μM (10 μM + 1 μM), and 20 μM (10 μM + 10 μM). c Anti-aggregation efficiency of two-drug combinations for platelets in the combinatorial screening tests for Volunteer 1. Based on the concentration of drug combinations, the two-drug combinations were divided into three groups: low concentration group (low group) including 2 μM Asp + 0.2 μM Tif, 2 μM Asp + 1 μM Tig, 0.2 μM Tif + 1 μM Tig; high concentration group (high group) including 20 μM Asp + 2 μM Tif, 20 μM Asp + 10 μM Tig, 2 μM Tif + 10 μM Tig; combinations of low and high concentrations (medium group) including 2 μM Asp + 10 μM Tig; 2 μM Tif + 1 μM Tig; 2 μM Asp + 2 μM Tif; 20 μM Asp + 1 μM Tig; 20 μM Asp + 0.2 μM Tif; 0.2 μM Tif +10 μM Tig. d Total heatmap of the anti-aggregation efficiency of two-drug combinations for the five volunteers. e The therapeutic effects of different drug combinations across various samples were compared, with samples having an anti-aggregation degree greater than 50% scored as 1 (indicated in orange) and those less than 50% scored as 0 (indicated in gray). f The top three drug combinations with the highest anti-aggregation efficiency in the medium group for the five volunteers